GE HealthCare Technologies may be too good of a bargain to pass up, according to Jefferies. The firm upgraded the health care stock to buy from hold and raised its price target to $103 per share from $95. Jefferies’ forecast calls for about 24% upside from Tuesday’s close. “GEHC has a renewed focus on growth and margin expansion through differential organic and inorganic investment,” analyst Matthew Taylor said. “This could be helped by healthy market growth, with GEHC having leading positions in Dx imaging (Ultrasound, Patient Care Solutions (PSC) and Pharm Diagnostics (PDx)).” GEHC YTD mountain GE HealthCare stock. Taylor noted the stock trades at around 17 to 18 times 2025 earnings estimates, below its peers and its own historical average. “Strong execution in a healthy market and new products (PDx, Imaging) could lead to beats and a re-rating; improving news out of China (12% of sales) could be another icing on the cake,” Taylor said. The analyst also forecasts GE HealthCare’s total addressable market will grow to about $110 billion by 2028, from roughly $90 billion in 2023, driven by a rise in demand and an aging population. GE HealthCare is up nearly 7% in early 2025, already outpacing its 2024 advance of just 1.1%. The stock soared more than 32% in 2023 after being spun off from General Electric. Analysts in general expect solid gains from the stock this year, with the average price target implying upside of nearly 16%, per LSEG. On top of that, 12 of the 20 who cover GE HealthCare rate it as a buy or strong buy.
